TAG Statement to Human Rights Council on Human Rights Concerns in the UAE
TAG participated in a hearing in Geneva, Switzerland to brief members of the Human Rights Council on human rights concerns in the United Arab Emirates (UAE).
Story: Cancer Drug Leads to ‘Drastic Decrease’ in HIV Infection in Lung Cancer Patient
November – December 2017 Examples of media coverage: Lung cancer drug may be early clue in hunt for HIV cure – The Independent, November 30, 2017 Cancer drug offers tantalising hope for HIV cure – The Guardian, November 30, 2017…
Suboptimal Immune Recovery on Antiretroviral Therapy: Causes, Consequences, and the Search for Solutions
On November 29, 2017, Treatment Action Group (TAG) hosted a webinar on suboptimal immune recovery despite HIV suppression by antiretroviral therapy. Presented by Richard Jefferys, TAG’s Basic Science, Vaccines and Cure Project Director, the webinar reviewed the possible causes and…
End the Epidemic Resources: Southern States EtE Meeting Summary and FAQs
Now is the time to end the HIV/AIDS epidemic in America’s southern states. Over the past four years, innovative Ending the Epidemic (EtE) plans have emerged in several jurisdictions across the nation following New York’s 2014 announcement that it will…
US Health & Human Services (HHS) Strategic Plan FY 2018-2022: TAG Comments to the Assistant Secretary for Planning and Evaluation
TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.
Division of AIDS Clinical Trials Networks Recompetition for 2020–2027 – Comments and Recommendations from TAG
TAG’s comments on the Divisions of AIDS (DAIDS) in advance of the recompetition of its clinical trials networks.
TAG Letter to House E&C Committee Opposing “Right to Try” Bills
TAG’s comments to the Health Subcommittee of the U.S. House of Representatives Energy and Commerce Committee, in association with its hearing, “Examining Patient Access to Investigational Drugs,” and the deliberations of H.R. 1020, the Compassionate Freedom of Choice Act of 2017, and S. 204, the Right to Try Act of 2017.
HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials
September 27, 2017 – The effectiveness of pre-exposure prophylaxis (PrEP) with the antiretroviral drug combination TDF/FTC (Truvada) raises questions regarding the design and conduct of trials of other candidate biomedical HIV prevention interventions, such as vaccines, passive immunization and alternative forms…
Advocacy organizations celebrate results as UnitedHealthcare swiftly reverses discriminatory PrEP practices
Fourteen health and social justice organizations from across the U.S. wish to celebrate the people-powered effort behind UnitedHealthcare responding so swiftly to demands that they improve access to the HIV drug Truvada for pre-exposure prophylaxis (PrEP)
TAG’s Annual Pipeline Report: Promising New HIV, TB & HCV Drugs and Diagnostics
Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.